- Home
- CLLS vs BACC Comparison
CLLS vs BACC Comparison
Compare CLLS & BACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.98
Company Overview
Basic Information| Metric | CLLS | BACC |
|---|---|---|
| Founded | 1999 | 2025 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 279.6M |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLLS | BACC |
|---|---|---|
| Price | $4.98 | $10.35 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 124.5K | ★ 319.1K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $58.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $9.95 |
| 52 Week High | $5.48 | $10.44 |
Technical Indicators
Market Signals| Indicator | CLLS | BACC |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | N/A |
| Support Level | $4.90 | N/A |
| Resistance Level | $5.35 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 85.56 | 0.00 |
Price Performance
Historical Comparison CLLS
BACC
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About BACC Blue Acquisition Corp. Class A Ordinary Shares
Blue Acquisition Corp is a blank check company.